Johnson & Johnson Hopes New Psoriasis Pill Icotyde Becomes a Major Revenue Driver
Johnson & Johnson has launched its new oral psoriasis treatment, Icotyde, which targets the same IL-23 receptor as injectable therapies like Tremfya. The company is optimistic about Icotyde's potential to become one of its top-selling drugs and bolster its immunology portfolio following Stelara’s loss of exclusivity.
Topics: Icotyde IL-23 inhibitors Johnson & Johnson psoriasis treatment Stelara Tremfya